Summary of findings 2. Glucocorticoid and epinephrine versus placebo: summary of findings.
| Glucocorticoid and epinephrine versus placebo for acute viral bronchiolitis in infants and young children | ||||||
| Patient or population: infants and young children with acute viral bronchiolitis Settings: outpatients Intervention: glucocorticoid and epinephrine versus placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Steroid versus placebo | No of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk1 | Corresponding risk | |||||
| Placebo | Steroid | |||||
|
Admissions (outpatients) Follow‐up: day 1 |
179 per 1000 | 115 per 1000 (72 to 186) | RR 0.65 (0.4 to 1.05) | 400 (1) | Low | NNT: not calculated for non‐significant findings |
|
Admissions (outpatients) Follow‐up: day 7 |
264 per 1000 | 169 per 1000 (116 to 251) |
RR 0.65 (0.44 to 0.95) |
400 (1) | Low | NNT: 11 (95% CI 7 to 76) (based on unadjusted analysis results) |
| *The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) CI: confidence interval NNT: number needed to treat RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1Assumed risk for admissions was based on the control group risk in the single study included (Plint 2009).